Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Cidara Therapeutics ( (CDTX) ).
Cidara Therapeutics announced that its Chief Financial Officer, Dr. Preetam Shah, will be leaving the company effective February 24, 2025, with Frank Karbe appointed as his successor. Dr. Shah’s departure is part of a mutual agreement, and he will serve as a consultant for six months post-departure, while Mr. Karbe joins with a robust background in finance and leadership roles in biopharmaceutical companies, potentially strengthening Cidara’s financial strategy and industry positioning.
More about Cidara Therapeutics
Cidara Therapeutics, Inc. is a biopharmaceutical company that focuses on the development of anti-infectives and immunotherapies. The company’s main focus is on creating innovative treatments for serious infections, including those that are resistant to current therapies.
YTD Price Performance: -12.31%
Average Trading Volume: 102,118
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $262M
See more insights into CDTX stock on TipRanks’ Stock Analysis page.
